Akynzeo Dosing for Chemotherapy-Induced Nausea and Vomiting
The recommended dose of Akynzeo is one capsule containing 300 mg netupitant plus 0.5 mg palonosetron, taken orally 1 hour before chemotherapy on day 1 only, combined with dexamethasone. 1
Specific Dosing by Chemotherapy Type
Highly Emetogenic Chemotherapy (Including Cisplatin)
Akynzeo capsules:
- Day 1: One capsule (300 mg netupitant/0.5 mg palonosetron) taken 1 hour before chemotherapy
- Dexamethasone: 12 mg on day 1 (30 minutes before chemotherapy), then 8 mg once daily on days 2-4 1, 2
This regimen is supported by the 2020 ASCO guidelines, which specifically list netupitant-palonosetron 300 mg/0.5 mg as a category 1 recommendation for highly emetogenic chemotherapy 2. The combination demonstrated superior efficacy compared to palonosetron alone, with complete response rates of 89.6% versus 76.5% in the overall phase (0-120 hours) 3.
Moderately Emetogenic Chemotherapy (Including Anthracycline-Cyclophosphamide)
Akynzeo capsules:
- Day 1: One capsule (300 mg netupitant/0.5 mg palonosetron) taken 1 hour before chemotherapy
- Dexamethasone: 12 mg on day 1 (30 minutes before chemotherapy)
- Days 2-3: No additional antiemetic treatment required 1
The pivotal trial in 1,455 patients receiving anthracycline-cyclophosphamide chemotherapy showed Akynzeo achieved 74.3% complete response versus 66.6% with palonosetron alone during the overall phase 4.
Important Administration Details
- Can be taken with or without food 1
- Single-dose administration on day 1 only - the long half-life of netupitant (90 hours) provides coverage through the delayed phase without repeat dosing 5
- Do not administer more frequently than once per chemotherapy cycle 1
Intravenous Formulation Alternative
For patients unable to swallow capsules, Akynzeo is available as an intravenous formulation:
- Fosnetupitant 235 mg/palonosetron 0.25 mg IV infused over 30 minutes, starting 30 minutes before chemotherapy 2, 1
- Same dexamethasone dosing as oral formulation
Key Clinical Considerations
The combination of netupitant and palonosetron in a single capsule offers several advantages:
- Dual-mechanism antiemetic coverage (NK1 and 5-HT3 receptor antagonism) in one dose
- Simplified regimen improves guideline adherence compared to multi-drug protocols
- Palonosetron's unique 40-hour half-life and higher receptor binding affinity provides superior delayed-phase protection compared to first-generation 5-HT3 antagonists 6
Critical pitfall to avoid: Do not reduce the dexamethasone dose to 8 mg on day 1 when using Akynzeo - the FDA-approved regimen specifies 12 mg dexamethasone (lower than the 20 mg used with palonosetron alone) because netupitant inhibits CYP3A4, increasing dexamethasone exposure 1.
The evidence consistently demonstrates that this single-capsule approach maintains efficacy across multiple chemotherapy cycles, with real-world data showing complete response rates of 97.5% in the acute phase and 95.09% in the delayed phase 7.